Applications for this meeting must be submitted by June 25, 2017. Please apply early, as some meetings become oversubscribed (full) before this deadline. If the meeting is oversubscribed, it will be stated here. Note: Applications for oversubscribed meetings will only be considered by the Conference Chair if more seats become available due to cancellations.
The goal of this meeting is to provide a dynamic forum for the active exchange of new discoveries and research tools in the advancing field of motor neuron diseases. Motor neuron diseases are a family of inherited and sporadic diseases affecting children and adults, typically are progressive and often fatal. The last 5+ years has seen tremendous growth in the understanding and development of relevant models for motor neuron diseases, such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). This reflects the discovery of disease causing gene mutations, multiple transgenic animal, fish and fly models and disease relevant human patient derived iPS cell models of brain neurons and glia. The field has seen a convergence of multiple different threads of basic and clinical science disciplines- basic synaptic circuitry, RNA processing, nuclear trafficking, neuron-glial interactions, to whole genome, transcriptome, epigenome and proteomic approaches to diverse pathways, clinical subtypes and disease relevant drug targeting pathways. More recently, even wearable devices monitoring health- are intersecting these basic biological approaches. The conference will bring together experts in a wide range of basic, clinical and translational neuroscience to discuss advances in the progress of understanding common and rare motor neuron diseases. Exciting new areas of research in these disease include dysfunction in RNA metabolism and protein homeostasis, with specific defects in nucleocytoplasmic trafficking, induction of endoplasmic reticulum stress, and impaired dynamics of ribonucleoprotein bodies such as RNA granules. In addition, the use and validation of imaging modalities, such as PET, as well as large population multi-omics data generation, to identify and validate dysfunctional pathways in animal models and patients, as well as the development of new therapies and biomarkers will be discussed. The extraordinary recent progress in understanding the biology of ALS provides new grounds for optimism that meaningful therapies for ALS will be identified. Recent studies indicate that pathways and drugs that may be relevant to these diseases, have far wider applicability to other neurological injuries.
The topics and speakers for the conference sessions are displayed below (italics denote discussion leaders). The Conference Chair is currently developing their detailed program, which will include the complete meeting schedule, as well as the talk titles for all speakers. The detailed program will be available by March 23, 2017. Please check back for updates.
Motor Neuron Gene Discovery
(Bryan Traynor / John Landers / David Goldstein)
Decoding the Role of TDP-43 and FUS in Neurodegeneration
(Philip Wong / Sami Barmada / Aaron Gitler / Clotilde Lagier-Tourenne)
RNA Granules and Proteinopathies in ALS
(James Shorter / Peter St George-Hyslop / Davide Trotti / Simon Alberti)
Dipeptide and RNA-Mediated Toxicity to Motor Neurons
(Dieter Edbauer / James Manley / Gunter Blobel)
Emerging Biomarkers of Motor Neuron Disease
(Nicholas Maragakis / Leonard Petrucelli / Martin Turner)
In Vivo Models of Motor Neuron Diseases
(Don Cleveland / Cat Lutz / Robert Baloh / Laura Ranum)
Motor Circuits and Cell Based Systems
(Charlotte Sumner / Siddharthan Chandran / George Mentis)
Axons and Glial Cells
(Richard Ransohoff / Erika Holzbaur / Beth Stevens / Richard Robitaille)
From Big Data Analysis to Therapeutics
(Kurt Fischbeck / Frank Bennett / Matthew Disney / Ernest Fraenkel)